The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
Open accessAbstract
Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2 inhibitors on the kidney is unknown. In addition, whether SGLT2 inhibitors have an anti-inflammatory or antioxidative stress effect is still unclear. In this study, to resolve these issues, we evaluated the effects of the SGLT2 inhibitor, dapagliflozin, using a mouse model of type 2 diabetes and cultured proximal tubular epithelial (mProx24) cells. Male db/db mice were administered 0.1 or 1.0 mg/kg of dapagliflozin for 12 weeks. Body weight, blood pressure, blood glucose, hemoglobin A1c, albuminuria and creatinine clearance were measured. Mesangial matrix accumulation and interstitial fibrosis in the kidney and pancreatic β-cell mass were evaluated by histological analysis. Furthermore, gene expression of inflammatory mediators, such as osteopontin, monocyte chemoattractant protein-1 and transforming growth factor-β, was evaluated by quantitative reverse transcriptase-PCR. In addition, oxidative stress was evaluated by dihydroethidium and NADPH oxidase 4 staining. Administration of 0.1 or 1.0 mg/kg of dapagliflozin ameliorated hyperglycemia, β-cell damage and albuminuria in db/db mice. Serum creatinine, creatinine clearance and blood pressure were not affected by administration of dapagliflozin, but glomerular mesangial expansion and interstitial fibrosis were suppressed in a dose-dependent manner. Dapagliflozin treatment markedly decreased macrophage infiltration and the gene expression of inflammation and oxidative stress in the kidney of db/db mice. Moreover, dapagliflozin suppressed the high-glucose-induced gene expression of inflammatory cytokines and oxidative stress in cultured mProx24 cells. These data suggest that dapagliflozin ameliorates diabetic nephropathy by improving hyperglycemia along with inhibiting inflammation and oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Navarro-González, J. F., Mora-Fernández, C., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,072
SGLT2 inhibition — a novel strategy for diabetes treatment
Chao, E. C., & Henry, R. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3180 · Cited by 822
A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy
Kanwar, Y. S., Sun, L., Xie, P., Liu, F.-Y., & Chen, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092150 · Cited by 775
Projecting the Number of Patients with End-Stage Renal Disease in the United States to the Year 2015
Gilbertson, D. T., Liu, J., Xue, J. L., Louis, T. A., Solid, C. A., Ebben, J. P., & Collins, A. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010112 · Cited by 719
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 421
Molecular physiology of sodium-glucose cotransporters.
Hediger, M. A., & Rhoads, D. B. (1994) · Physiological Reviews · doi:10.1152/physrev.1994.74.4.993 · Cited by 417
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
Self-citationVallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y., & Makino, H. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2586 · Cited by 298
Self-citationDeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Fujimori, Y., Katsuno, K., Nakashima, I., Ishikawa-Takemura, Y., Fujikura, H., & Isaji, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140210 · Cited by 221
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Jurczak, M. J., Lee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Frederick, D. W., Pongratz, R. L., Zhao, X., Moeckel, G. W., Samuel, V. T., Whaley, J. M., et al. (2011) · Diabetes · doi:10.2337/db10-1328 · Cited by 219
Ohga, S., Shikata, K., Yozai, K., Okada, S., Ogawa, D., Usui, H., Wada, J., Shikata, Y., & Makino, H. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00288.2005 · Cited by 203
Self-citationEffects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Kojima, N., Williams, J. M., Takahashi, T., Miyata, N., & Roman, R. J. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203869 · Cited by 142
Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
Plosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 101
Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., & Kawabe, Y. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12269 · Cited by 98
MacDonald, F., Peel, J. E., Jones, H. B., Mayers, R. M., Westgate, L., Whaley, J. M., & Poucher, S. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01291.x · Cited by 91
Matsushita, Y., Ogawa, D., Wada, J., Yamamoto, N., Shikata, K., Sato, C., Tachibana, H., Toyota, N., & Makino, H. (2011) · Diabetes · doi:10.2337/db10-1361 · Cited by 73
Self-citationChen, L., & Leung, P. S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12064 · Cited by 72
Whaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 68
Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy
Tachibana, H., Ogawa, D., Matsushita, Y., Bruemmer, D., Wada, J., Teshigawara, S., Eguchi, J., Horiguchi, C. S., Uchida, H. A., Shikata, K., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010022 · Cited by 54
Self-citationChen, L., Klein, T., & Leung, P. S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480970 · Cited by 49
Vlassara, H., Cai, W., Chen, X., Serrano, E. J., Shobha, M., Uribarri, J., Woodward, M., & Striker, G. E. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls195 · Cited by 32
SGLT2 inhibitors enter crowded diabetes space
Bouchie, A. J. (2013) · Nature Biotechnology · doi:10.1038/nbt0613-469 · Cited by 16
Cited by
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
“Our present results are in good agreement with previous reports regarding various SGLT2 inhibitors [17-19,41,44] including empagliflozin [16].”
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Metadata
- Authors
- Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., Takei, K., & Makino, H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-24
- Volume
- 9
- Issue
- 6
- Pages
- e100777
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2023244494
- Cited by
- 341
- References
- 29
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.